Sysmex (OTCMKTS:SSMXY) Stock Price Down 1.5% - Here's Why

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report)'s stock price was down 1.5% during trading on Tuesday . The company traded as low as $16.16 and last traded at $16.54. Approximately 100,197 shares changed hands during mid-day trading, a decline of 13% from the average daily volume of 115,013 shares. The stock had previously closed at $16.79.

Sysmex Stock Performance

The stock has a market capitalization of $10.41 billion, a price-to-earnings ratio of 29.54 and a beta of 1.14. The company has a quick ratio of 2.30, a current ratio of 2.97 and a debt-to-equity ratio of 0.12. The stock's 50-day simple moving average is $17.02 and its 200 day simple moving average is $18.02.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.04). Sysmex had a net margin of 10.56% and a return on equity of 11.81%. The firm had revenue of $958.89 million during the quarter, compared to analyst estimates of $991.22 million. Analysts expect that Sysmex Corporation ADR will post 0.57 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.